Datamonitor launches
CNS Review
The CNS Review brings you
the latest news, analysis and research in the CNS industry. It covers all
the major current business issues and events, including R&D, licensing
deals, alliances and joint ventures, and regulatory decisions.
Scope
-
Strategic insight
into the future shape of CNS companies and markets
-
The most significant
CNS industry news compiled into one monthly update
-
Expert analysis into
the implications of the month's important CNS industry events
-
Insight into the
future shape of the market for players at all levels
-
All the month's CNS
stories in headline and summary form
Report Highlights
Out of the dozens of
topics covered in this month's review, the most important include:
* Serono and Pfizer
signed an agreement to co-promote Serono's multiple sclerosis treatment,
Rebif, in the US. Rebif is approved for use in the US and Europe and is
registered for use in more than 70 countries worldwide.
* Janssen's substantial
slice of the lucrative antipsychotics market is under threat from Pfizer's
Geodon, which will enjoy substantial first-to-market advantage following
regulatory delays to injectable Risperdal.
Reasons to Purchase
Not only keeps you
updated about industry events - it also gives you opinion and insight
Draws upon Datamonitor
analysts' extensive experience to bring you our perspective on the impact
of the latest events
Provides you with your
own news archive to track company and industry progress, giving you an
extensive reference to relevant events and issues
View
pdf brochure
Click
here to purchase online
